Protalix ( (PLX) ) has issued an update.
Protalix BioTherapeutics is set to present promising data from their phase I trial of PRX-115, a novel treatment for uncontrolled gout, at the ACR Convergence 2024. This showcases their innovative plant cell-based protein expression system, ProCellEx, which has already led to FDA-approved products. Investors and market watchers should note Protalix’s strategic partnerships and expanding pipeline targeting key pharmaceutical markets.
For detailed information about PLX stock, go to TipRanks’ Stock Analysis page.
